Visceral adipose tissue: Emerging role of gluco- and mineralocorticoid hormones in the setting of cardiometabolic alterations

Annals of the New York Academy of Sciences

Volumn 1264, Issue 1, 2012, Pages 87-102

  Boscaro, Marco ^a   Giacchetti, Gilberta ^a   Ronconi, Vanessa ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Adipose tissue; Glucocorticoids; Mineralocorticoids

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MINERALOCORTICOID;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ARTICLE; CARDIOVASCULAR PARAMETERS; CELL DIFFERENTIATION; ENDOCRINE GLAND; GENETIC POLYMORPHISM; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INTRAABDOMINAL FAT; LIPID STORAGE; METABOLIC PARAMETERS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIMARY HYPERALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 84864844078     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06597.x     Document Type: Article

References (160)

1. Harris, M.I., K.M. Flegal, C.C. Cowie, et al . 1998. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21: 518-524.
2. Harris, M.I. 1998. Diabetes in America: epidemiology and scope of the problem. Diabetes Care 21: C11-C14.
3. Ogden, C.L., M.D. Carroll, L.R. Curtin, et al. 2006. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295: 1549-1555.
4. Sowers, J.R., M. Epstein & E.D. Frohlich . 2001. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37: 1053-1059.
5. Cinti, S., C. Zancanaro, A. Sbarbati, et al . 1989. Immunoelecton microscopal identification of the uncoupling protein in brown adipose tissue mitochondria. Biol. Cell. 67: 359-362.
6. Virtanen, K.A., M.E. Lidell, J. Orava, et al . 2009. Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 360: 1518-1525.
7. Rothwell, N.J. & M.J. Stock . 1979. A role for brown adipose tissue in diet-induced thermogenesis. Nature 281: 31-35.
8. Wisse, B.E. 2004. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 15: 2792-2800.
9. Hotamisligil, G.S., N.S. Shargill & B.M. Spiegelman .1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-link insulin resistance. Science 259: 87-91.
10. Wellen, K.E., & G.S. Hotamisligil . 2003. Obesity-induced inflammation changes in adipose tissue. J. Clin. Invest. 112: 1785-1788.
11. Weisberg, S.P., D. Mc Cann, M. Desai, et al . 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112: 1796-1808.
12. Xu, H., G.T. Barnes, Q. Yang, et al . 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830.
13. Cinti, S., G. Mitchell, G. Barbatelli, et al . 2005. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid. Res. 46: 2347-2355.
14. Maury, E., K. Ehala-Aleksejev, Y. Guiot, et al . Adipokines oversecreted by omental adipose tissue in human obesity. Am. J. Physiol. Endocrinol. Metab. 293: E656-E665.
15. Zhang, Y., R. Proenca, M. Maffei, et al . 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432.
16. Maeda, K., K. Okubo, I. Shimomura, et al . 1996. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1). Biochem. Biophys. Res. Commun. 221: 286-289.
17. Sethi, J.K. & A.J. Vidal-Puig . 2007. Adipose tissue function and plasticity orchestrate nutritional adaptation. J. Lipid Res. 48: 1253-1262.
18. Ahima, R.S. & J.S. Flier . 2000. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 11: 327-332.
19. Shimomura, I., R.E. Hammer, S. Ikemoto, et al . 1999. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401: 73-76.
20. Eckel, R.H. & R.M. Krauss . 1998. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 97: 2099-2100.
21. Donahue, R.P., R.D. Abbott, E. Bloom, et al . 1987. Central obesity and coronary heart disease in men. Lancet 1: 821-824.
22. Després, J.P., I. Lemieux, J. Bergeron, et al . 2008. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol. 28: 1039-1049.
23. Lean, M.E., T.S. Han & J.C. Seidell . 1998. Impairment of health and quality of life in people with large waist circumference. Lancet 351: 853-856.
24. Ford, E.S.G. & W.H. Dietz . 2002. Prevalence of the metabolic syndrome among U.S. adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287: 356-359.
25. Stumvoll, M., B.J. Goldstein & T.W. van Haeften . 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346.
26. Zierath, J.R. & H. Wallberg-Henriksson . 2002. From receptor to effector: insulin signal transduction in skeletal muscle from type II diabetic patients. Ann. N.Y. Acad. Sci. 967: 120-134.
27. Mokdad, A.H., E.S. Ford, B.A. Bowman, et al . 2003. Prevalence of obesity, diabetes, and obesity-related health risk factors. 2001. JAMA 289: 76-79.
28. De Luca, C. & J.M. Olefsky . 2008. Inflammation and insulin resistance. FEBS Lett. 582: 97-105.
29. Wang, P., E. Mariman, J. Renes, et al . 2008. The secretory function of adipocytes in the physiology of white adipose tissue. J. Cell. Physiol. 216: 3-13.
30. Shoelson, S.E., L. Herrero & A. Naaz . 2007. Obesity, inflammation, and insulin resistance. Gastroenterology 132: 2169-2180.
31. Villena, J.A., S. Roy, E. Sardaki-Nagy, et al . 2004. Desnutrin, an adipocyte gene encoding a novel patratin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increase triglyceride hydrolysis. J. Biol. Chem. 279: 47066-47075.
32. Foley, J.E. 1992. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 15: 773-784.
33. Ginsberg, H.N. 2006. Review: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J. Clin. Endocrinol. Metab. 91: 383-392.
34. Cheung, B.M. & C. Li . 2012. Diabetes and hypertension: is there a common metabolic pathway? Curr. Atheroscler. Rep. 14: 160-166.
35. Baum, M. 1987. Insulin stimulates volume absorption in the proximal convoluted tubule. J. Clin. Invest. 79: 1104-1109.
36. Vierhapper, H., W. Waldhausl & P. Nowontny . 1983. The effect of insulin on the rise in blood pressure and plasma aldosterone after angiotensin II in normal man. Clin. Sci. 64: 383-386.
37. Deibert, D.C. & R.A. DeFronzo . 1980 Epinephrine-induced insulin resistance in man. J. Clin. Invest. 65: 717-721.
38. Rocchini, A.P., J. Key, D. Bondie, et al . 1989. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N. Engl. J. Med. 21: 580-585.
39. Stout, R.W., E. Bierman & R. Ross . 1975. Effect of insulin on the proliferation of cultured pnmate arterial smooth muscle cells. Circ. Res. 36: 319-327.
40. Sowers, J.R. 2004. Insulin resistance and hypertension. Am. J. Physiol. Heart. Circ. Physiol. 286: H1597-H1602.
41. McFarlane, S.I., M. Banerji & J.R. Sowers . 2001. Insulin resistance and cardiovascular disease. J. Clin. Endocrinol. Metab. 86: 713-718.
42. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. 2002. Circulation 106: 3143-3421.
43. Grundy, S.M., H.B. Brewer, J.I. Cleeman, et al . 2004. Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 109: 433-438.
44. Pasquali, R., V. Vicennati, M. Cacciari, et al . 2006. The Hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann. N.Y. Acad. Sci. 1083: 111-128.
45. Rebuffè-Scrive, M., U.A. Walsh, B. McEwen, et al. 1992. Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiol. Behav. 52: 583-590.
46. Brunner, E.J., H. Hemingway, B.R. Walker, et al . 2002. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 106: 2659-2665.
47. Epel, E.S., B. McEwen, T. Seeman, et al . 2000. Stress and body shape: stress-induced cortisol secretion is consistently greater among women with central fat. Psychosom. Med. 62: 623-632.
48. Pasquali, R. & V. Vicennati . 2000. Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int. J. Obes. Relat. Metab. Disord. 24(Suppl): S47-S49.
49. Ward, A.M., C.H. Fall, C.E. Stein, et al . 2003. Cortisol and the metabolic syndrome in South Asians. Clin. Endocrinol. 58: 500-505.
50. Korbonits, M., P.J. Trainer, M.L. Nelson, et al . 1996. Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution. Clin. Endocrinol. 45: 699-706.
51. Pasquali, R., B. Anconetani, R. Chattat, et al . 1996. Hypothalamic-pituitary-adrenal axis activity and its relationship to the autonomic nervous system in women with visceral and subcutaneous obesity: effects of the corticotropin-releasing factor/arginine-vasopressin test and of stress. Metabolism 45: 351-356.
52. Pasquali, R., B. Ambrosi, D. Armanini, et al . 2002. Study Group on Obesity of the Italian Society of Endocrinology. Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. J. Clin. Endocrinol. Metab. 87: 166-175.
53. Misra, M., M.A. Bredella, P. Tsai, et al . 2008. Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls. Am. J. Physiol. Endocrinol. Metab. 295: E385-E392.
54. Marin, P., N. Darin, T. Amemiya, et al . 1992. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 41: 882-886.
55. Pasquali, R., S. Cantobelli, F. Casimirri, et al . 1993. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J. Clin. Endocrinol. Metab. 77: 341-346.
56. Manenschijn, L., E.L. van den Akker, S.W. Lamberts, et al . 2009. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann. N.Y. Acad. Sci. 1179: 179-198.
57. Francke, U. & B.E. Foellmer . 1989. The glucocorticoid receptor gene is in 5q31-q32. Genomics 4: 610-612.
58. Theriault, A., E. Boyd, S.B. Harrap, et al. 1989. Regional chromosomal assignement of the human glucocorticoid receptor gene to 5q31. Hum. Genet. 83: 289-291.
59. Hollenberg, S.M., C. Weinberger, E.S. Ong, et al . 1985. Primary structure and expression of functional human glucocorticoid receptor cDNA. Nature 318: 635-641.
60. Lewis-Tuffin, L.J., C.M. Jewell, R.J., Bienstock, et al . 2007. Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active. Mol. Cell. Biol. 27: 2266-2282.
61. Lamberts, S.W., A.T. Huizenga, P. de Lange, et al . 1996. Clinical aspects of glucocorticoid sensitivity. Steroids 61: 157-160.
62. Russcher, H., P. Smit, E.L. van den Akker, et al . 2005. Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J. Clin. Endocrinol. Metab. 90: 5804-5810.
63. van Rossum, E.F. & S.W. Lamberts . 2004. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res. 59: 333-357.
64. van Rossum, E.F.C. & S.W.J. Lamberts . 2004. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res. 59: 333-357.
65. Dobson, M.G., C.P. Redfern, N. Unwin, et al . 2001. The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus. J. Clin. Endocrinol. Metab. 86: 2270-2274.
66. Di Blasio, A.M., E.F. van Rossum, S. Maestrini, et al . 2003. The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin. Endocrinol. 59: 68-74.
67. Buemann, B., M.C. Vohl, M. Chagnon, et al . 1997. Abdominal visceral fat is associated with a BclI restriction fragment length polymorphism at the glucocorticoid receptor gene locus. Obes. Res. 5: 186-192.
68. Lin, R.C., X.L. Wang, B. Dalziel, et al . 2003. Association of obesity, but not diabetes or hypertension, with glucocorticoid receptor N363S variant. Obes. Res. 11: 802-818.
69. Ukkola, O., L. Perusse, Y.C. Chagnon, et al . 2001. Interactions among the glucocorticoid receptor, lipoprotein lipase and adrenergic receptor genes and abdominal fat in the Quebec Family Study. Int. J. Obes. Relat. Metab. Disord. 25: 1332-1339.
70. Rutters, F., A.G. Nieuwenhuizen, S.G. Lemmens, et al . 2011. Associations between anthropometrical measurements, body composition, single-nucleotide polymorphisms of the hypothalamus/pituitary/adrenal (HPA) axis and HPA axis functioning. Clin. Endocrinol. 74: 679-686.
71. Voorhoeve, P.G., E.L. van den Akker, E.F. van Rossum, et al . 2009. Glucocorticoid receptor gene variant is associated with increased body fatness in youngsters. Clin. Endocrinol. 71: 518-523.
72. Rosmond, R., C. Bouchard & P. Bjorntorp . 2001. Tsp509I polymorphism in exon 2 of the glucocorticoid receptor gene in relation to obesity and cortisol secretion: cohort study. Br. Med. J. 322: 652-653.
73. Echwald, S.M., T.I. Sorensen, T. Andersen, et al . 2001. The Asn363Ser variant of the glucocorticoid receptor gene is not associated with obesity or weight gain in Danish men. Intl. J. Obes. Relat. Metab. Disord. 25: 1563-1565.
74. Lin, R.C.Y., W.Y.S. Wang & B.J. Morris . 1999. High penetrance, overweight, and glucocorticoid receptor variant: case-control study. Br. Med. J. 349: 1337-1338.
75. Huizenga, N.A., J.W. Koper, P. De Lange, et al . 1998. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J. Clin. Endocrinol. Metab. 83: 144-151.
76. Syed, A.A., J.A. Irving, C.P. Redfern, et al . 2006. Association of glucocorticoid receptor polymorphism A3669G in exon 9beta with reduced central adiposity in women. Obesity 14: 759-764.
77. Trementino, L., G. Appolloni, C. Concettoni, et al . 2012. Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome. Eur. J. Endocrinol. 166: 35-42.
78. Cellini, E., G. Castellini, V. Ricca, et al . 2010. Glucocorticoid receptor gene polymorphisms in Italian patients with eating disorders and obesity. Psychiatr. Genet 20: 282-288.
79. Walker, B.R. 2001. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. 86: 1418-1421.
80. Walker, B.R., S. Soderberg, B. Lindahl, et al . 2000. Independent effects of obesity and cortisol in predicting cardiovascular risk factors in men and women. J. Intern. Med. 247: 198-204.
81. Travison, T.G., A.B. O'Donnell, A.B. Araujo, et al . 2007. Cortisol levels and measures of body composition in middle-aged and older men. Clin. Endocrinol. 67: 71-77.
82. Duclos, M., P. Marquez Pereira, P. Barat, et al . 2005. Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes. Res. 13: 1157-1166.
83. Gathercole, L.L., S.A. Morgan, I.J. Bujalska, et al . 2011. Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue. PLoS One 6: e26223.
84. Masuzaki, H., J. Paterson, H. Shinyama, et al . 2001. A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170.
85. Paterson, J.M., N.M. Morton, C. Fievet, et al . 2004. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. USA 101: 7088-7093.
86. Morton, N.M., J.M. Paterson, H. Masuzaki, et al . 2004. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53: 931-938.
87. Mariniello, B., V. Ronconi, S. Rilli, et al . 2006. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur. J. Endocrinol. 155: 435-441.
88. Barf, T., J. Vallgårda, R. Emond, et al . 2002. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent inhibitors of the 11β-hydroxysteroid dehydrogenase type I. J. Med. Chem. 45: 3813-3815.
89. Olson, S., S.D. Aster, K. Brown, et al . 2005. Adamantyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett. 15: 4359-4362.
90. Yuan, C., D.J. St Jean Jr., Q. Liu, et al . 2007. The discovery of 2-anilinothiazolones as 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 17: 6056-6061.
91. Rosenstock, J., S. Banarer, V.A. Fonseca, et al . 2010. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33: 1516-1522.
92. Tomlinson, J.W., M. Sherlock, B. Hughes, et al . 2007. Inhibition of 11{beta}-HSD1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J. Clin. Endocrinol. Metab. 92: 857-864.
93. Carling, D., V.A. Zammit & D.G. Hardie . 1987. A common biclycic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett. 223: 217-222.
94. Hardie, D.G., D. Carling & A.T.R Sim . 1989. The AMP-activated protein kinase: a multisubstrate regulator of lipid metabolism. Trends Biochem. Sci. 14: 20-23.
95. Lim, C.T., B. Kola & M. Korbonits . 2010. AMPK as mediator of hormonal signalling. J. Mol. Endocrinol. 44: 87-97.
96. Divertie, G.D., M.D. Jensen & J.M. Miles . 1991. Stimulation of lipolysis in humans by physiological hypercortisolemia. Diabetes 40: 1228-1232.
97. Djurhuus, C.B., C.H. Gravholt, S. Nielsen, et al . 2002. Effects of cortisol on lipolysis and regional interstitial glycerol levels in human. Am. J. Physiol.Endocrinol. Metab. 283: E172-E177.
98. Christ-Crain, M., B. Kola, F. Lolli, et al . 2008. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 22: 1672-1683.
99. Viana, A.Y., H. Sakoda, M. Anai, et al . 2006. Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. Diab. Res. Clin. Pract. 73: 135-142.
100. Brown, P.D., S. Badal, S. Morrison, et al . 2007. Acute impairment of insulin signalling by dexamethasone in primary cultured rat skeletal myocytes. Mol. Cell. Biochem. 297: 171-177.
101. Lundgren, M., J. Buren, T. Ruge, et al . 2004. Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J. Clin. Endocrinol. Metab. 89: 2989-2997.
102. Koricanac, G., E. Isenovic, V. Stojanovic-Susulic, et al . 2006. Time dependent effects of dexamethasone on serum insulin level and insulin receptors in rat liver and erythrocytes. Gen. Physiol. Biophys. 25: 11-24.
103. El-Atat, F., A. Aneja, S. Mcfarlane, et al . 2003. Obesity and hypertension. Endocrinol. Metab. Clin. North Am. 32: 823-854.
104. Zhang, R. & E. Reisin . 2000. Obesity-hypertension: the effects on cardiovascular and renal systems. Am. J. Hypertens. 13: 1308-1314.
105. Reaven, G.M., H. Lithell & L. Landsberg . 1996. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med. 334: 374-381.
106. Hansson, L., L.H. Lindholm, L. Niskanen, et al . 1999. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 353: 611-616.
107. Yusuf, S., P. Sleight, B. Pogue, et al . 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342: 145-153.
108. Lindholm, L.H., H. Ibsen, K. Borch-Johnsen, et al . 2002. Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J. Hypertens. 20: 1879-1886.
109. Jandeleit-Dahm, K.A.M., C. Tikellis, C.M. Reid, et al . 2005. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens. 23: 463-473.
110. Furuhashi, M., N. Ura, H. Takizawa, et al . 2004. Blockade of the renin-angiotensin systemdecreases adipocyte size with improvement in insulin sensitivity. J. Hypertens. 22: 1977-1982.
111. Mori, Y., Y. Itoh & N. Tajima . 2007. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am. J. Hypertens. 20: 431-436.
112. Zorad, S., J.T. Dou, J. Benicky, et al . 2006. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARγ. Europ. J. Pharmacol. 552: 112-122.
113. Sharma, A.M., J. Janke, K. Gorzelniak, et al . 2002. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40: 609-611.
114. Cooper, R., N. McFarlane-Anderson, F.I. Bennett, et al . 1997. ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J. Hum. Hypertens. 11: 107-111.
115. Messerli, F.H., B. Christie, J.G. DeCarvalho, et al . 1981. Obesity and essential hypertension. Hemodinamycs, intravascular volume, sodium excretion, and plasma renin activity. Arch. Intern. Med. 141: 81-85.
116. Massiera, F., M. Bloch-Faure, D. Ceiler, et al . 2001. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 15: 2727-2729.
117. Faloia, E., C. Gatti, M.A. Camilloni, et al . 2002. Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. J. Endocrinol. Invest. 25: 309-314.
118. Giacchetti, G., E. Faloia, B. Mariniello, et al . 2002. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am. J. Hypertens. 15: 381-388.
119. Janke, J., S. Engeli, K. Gorzelniak, et al . 2002. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51: 1699-1707.
120. Rondinone, C.M., D. Rodbard & M.E. Baker . 1993. Aldosterone stimulates differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology 132: 2421-2426.
121. Zennaro, M.C., D. Le Menuet, S. Viengchareun, et al . 1998. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J. Clin. Invest. 101: 1254-1260.
122. Fu, M., T. Sun, A.L. Bookout, et al . 2005. A nuclear receptor atlas: 3T3-L1 adipogenesis. Mol. Endocrinol. 19: 2437-2450.
123. Caprio, M., B. Feve, A. Claes, et al . 2007. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 21: 2185-2194.
124. Caprio, M., A. Antelmi, G. Chetrite, et al . 2011. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 152: 113-125.
125. Goodfriend, T.L., D.E. Kelley, B.H. Goodpaster, et al . 1999. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes. Res. 7: 355-362.
126. El Gharbawy, A.H., V.S. Nadig, J.M. Kotchen, et al . 2001. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 37: 845-850.
127. Engeli, S., J. Bohne, K. Gorzelniak, et al . 2005. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45: 356-362.
128. Rossi, G.P., A. Belfiore, G. Bernini, et al . 2008. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J. Clin. Endocrinol. Metab. 93: 2566-2571.
129. Ehrhart-Bornstein, M., V. Lamounier-Zepter, V. Schraven, et al . 2003. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl. Acad. Sci. USA 100: 14211-14216.
130. Strazzullo, P., R. Iacone, L. Iacoviello, et al . 2003. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Heart Study. Ann. Intern. Med. 138: 17-23.
131. Goodfriend, T.L., D.L. Ball, B.M. Egan, et al . 2004. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43: 358-363.
132. Nagase, M., S. Yoshida, S. Shibata, et al . 2006. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J. Am. Soc. Nephrol. 17: 3438-3446.
133. Funder J.W. 2005. The nongenomic actions of aldosterone. Endocr. Rev. 26: 313-321.
134. Rossi, G.P., L.A. Sechi, G. Giacchetti, et al . 2008. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol. Metab. 19: 88-90.
135. Giacchetti, G., L.A. Sechi, S. Rilli, et al . 2005. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol. Metab. 16: 120-126.
136. Fallo, F., F. Veglio, C. Bertello, et al . 2006. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J. Clin. Endocrinol. Metab. 91: 454-459.
137. Ronconi, V., F. Turchi, S. Rilli, et al . 2010. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. Nutr. Metab. Cardiovasc. Dis. 20: 93-100.
138. Conn, J.W., R.F. Knopf & R.M. Nesbit . 1964. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am. J. Surg. 107: 159-172.
139. Carranza, M.C., A. Torres & C. Calle . 1991. Decreased insulin receptor number and affinity in subcutaneous adipose tissue in a patient with primary hyperaldosteronism. Rev. Clin. Exp. 188: 414-417.
140. Shimamoto, K., M. Shiiki, T. Ise, et al . 1994. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism. J. Hum. Hypertens. 10: 755-759.
141. Widimsky, J., G. Sindelka, T. Haas, et al . 2000. Impaired insulin action in primary aldosteronism. Physiol. Res. 49: 241-244.
142. Catena, C., R. Lapenna, S. Baroselli, et al . 2006. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin. Endocrinol. Metab. 91: 3457-3463.
143. Devenport, L.D., K.G. Goodwin & P.M. Hopkins . 1985. Continuous infusion of aldosterone: correlates of body weight gain. Pharmacol. Biochem. Behav. 22: 707-709.
144. Kraus, D., J. Jager, B. Meier, et al . 2005. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm. Metab. Res. 37: 455-459.
145. Skrha, J., T. Haas, G. Sindelka, et al . 2004. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J. Clin. Endocrinol. Metab. 89: 135-141.
146. Widimsky, J., B. Strauch, G. Sindelka, et al . 2001. Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus? Physiol. Res. 50: 603-607.
147. Giacchetti, G., V. Ronconi, F. Turchi, et al . 2007. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J. Hypertens. 25: 177-186.
148. Reincke, M., C. Meisinger, R. Holle, et al . 2010. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry. Horm. Metab. Res. 42: 435-439.
149. Sindelka, G., J. Widimský, T. Haas, et al . 2000. Insulin action in primary aldosteronism before and after surgical or pharmacological treatment. Exp. Clin. Endocrinol. Diabetes 108: 21-25.
150. Corry, D.B. & M.L. Tuck . 2003. The effect of aldosterone on glucose metabolism. Curr. Hypertens. Rep. 5: 106-109.
151. Haluzik, M., G. Sindelka, J. Widimsky Jr., et al . 2002. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationship to insulin sensitivity. J. Hum. Hypertens. 16: 41-45.
152. Torpy, D.J., S.R. Bornstein, W. Taylor, et al . 1999. Leptin levels are suppressed in primary aldosteronism. Horm. Metab. Res. 31: 533-536.
153. Fallo, F., P. Della Mea, N. Sonino, et al . 2007. Adiponectin and insulin sensitivity in primary aldosteronism. Am. J. Hypertens. 20: 855-861.
154. Iacobellis, G., L. Petramala, D. Cotesta, et al . 2010. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J. Clin. Endocrinol. Metab. 95: 2391-2398.
155. Ronconi, V., F. Turchi, G. Appolloni, et al . 2012. Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. Curr. Vasc. Pharmacol. 10: 238-246.
156. Ehrhart-Bornstein, M., K. Arakelyan, A.W. Krug, et al . 2004. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr. Res. 30: 865-870.
157. Urbanet, R., C. Pilon, A. Calcagno, et al . 2010. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 95: 4037-4042.
158. Salmenniemi, U., E. Ruotsalainen, J. Pihlajamaki, et al . 2004. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 110: 3842-3848.
159. Hitomi, H., H. Kiyomoto, A. Nishiyama, et al . 2007. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50: 750-755.
160. Lastra, G., A. Whaley-Connell, C. Manrique, et al . 2008. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am. J. Physiol. Endocrinol. Metab. 295: E110-E116.